A5063133761- Lymphoma Diagnosis and Treatment
- T-cell and Retrovirus Studies
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Cutaneous lymphoproliferative disorders research
- Protein Degradation and Inhibitors
- Histone Deacetylase Inhibitors Research
- Epigenetics and DNA Methylation
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Acute Lymphoblastic Leukemia research
- Galectins and Cancer Biology
- CNS Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Cancer-related gene regulation
- Cytokine Signaling Pathways and Interactions
- Immunotherapy and Immune Responses
- Eosinophilic Disorders and Syndromes
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Toxin Mechanisms and Immunotoxins
- Cancer Immunotherapy and Biomarkers
- Protein Tyrosine Phosphatases
- Cancer-related molecular mechanisms research
The Ohio State University Wexner Medical Center
2022-2025
The Ohio State University
2019-2025
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2019-2023
University of Michigan
2018-2019
St. Luke's Hospital
2016
Mayo Clinic
2016
Mayo Clinic in Arizona
2015
Texas A&M Health Science Center
2012-2014
Scott & White Memorial Hospital
2012
Mitchell Institute
2009
Significance The clinical trials with human mesenchymal stem/progenitor cells (hMSCs) from bone marrow and other tissues are proceeding even though cultures of the heterogeneous there is large variability among preparations hMSCs due to differences donors, culture conditions, inconsistent tissue sampling. However, currently no in vitro bioassay for evaluation hMSC efficacy vivo. Therefore, value data obtained current may well be compromised by variations quality used. This study provides,...
Neoplasms originating from thymic T-cell progenitors and post-thymic mature subsets account for a minority of lymphoproliferative neoplasms. These derived neoplasms, while molecularly genetically heterogeneous, exploit transcription factors signaling pathways that are critically important in normal biology, including those implicated antigen-, costimulatory-, cytokine-receptor signaling. The factor GATA-3 regulates the growth proliferation both immature T cells has recently been most common...
ABSTRACT Background Treatments for adolescent and young adult (AYA) patients with mature B‐cell lymphomas (MBCL) differ between versus pediatric centers, data are scarce regarding comparative toxicities outcomes. Procedures We identified AYA (age 12–39) MBCL seen 2011 2021 at an (AC) (PC) tertiary cancer center. Data baseline characteristics, adverse events, long‐term outcomes were collected. Results A total of 173 identified, 20 in the PC 153 AC. During treatment, more unplanned...
Relapsed or refractory classical Hodgkin lymphoma (cHL) remains a difficult treatment challenge. Although checkpoint inhibitors (CPI) have provided clinical benefit for these patients, responses are generally not durable, and progression eventually occurs. Discovering combination therapies which maximize the immune response of CPI therapy may overcome this limitation. We hypothesized that adding ibrutinib to nivolumab will lead deeper more durable in cHL by promoting favorable...
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive, rare of killer (NK) cell origin with poor clinical outcomes. Here we used phenotypic and molecular profiling, including epigenetic analyses, to investigate how ENKTL ontogeny relates normal NK-cell development. We demonstrate that neoplastic NK cells are stably, but reversibly, arrested at earlier stages maturation. Genes downregulated in the most immature tumors were associated polycomb silencing along genomic gain...
Abstract Purpose: Many peripheral and cutaneous T-cell lymphoma (CTCL) subtypes are poorly responsive to conventional chemotherapeutic agents associated with dismal outcomes. The zinc finger transcription factor GATA-3 the transcriptional program it instigates oncogenic highly expressed in various neoplasms. Posttranslational acetylation regulates DNA binding target gene expression. Given widespread use of histone deacetylase inhibitors (HDACi) relapsed/refractory CTCL, we sought examine...
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Robust biomarkers and a complete understanding of CAR function in the postinfusion phase remain limited. Here, we used 37-color spectral flow cytometry panel to perform high dimensional single-cell analysis samples 26 patients treated with CD28 costimulatory domain containing commercial T cells NHL focused on computationally gated CD8+ cells. We found that...
The optimal timing for administering high-dose methotrexate (HDMTX) when combined with (R)CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone, with/without rituximab) is unclear. Recent data showed that the administration of prophylactic HDMTX before day 10 R- CHOP may lead to fewer treatment delays. Herein, we report our experience administered on 1 in patients aggressive non-Hodgkin lymphoma (NHL). We identified 140 treated ≥1 cycle prophylaxis against (n = 84) or 56) central...
Peripheral T-cell lymphomas (PTCL) are agressive that develop from mature T cells. The most common PTCLs genetically, molecularly, and clinically diverse generally associated with dismal outcomes. While Notch signaling plays a critically important role in both the development of immature cells their malignant transformation, its PTCL is poorly understood, despite increasingly appreciated function regulating proliferation differentiation Here, we demonstrate receptors Delta-like family...
Relapsed or refractory Hodgkin lymphoma (R/R HL) is a challenging disease with limited treatment options beyond brentuximab vedotin and checkpoint inhibitors. Herein we present the time-trend analysis of R/R HL patients who received allogeneic hematopoietic cell transplantation (allo-HCT) at our center from 2001-2017.The were divided into two distinct cohorts: era1 (2001-2010), era2 (2011-2017). The primary endpoint was overall survival (OS). Secondary endpoints included progression-free...